tiprankstipranks

Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports

A preprint article posted on September 11 by medRxiv detailed results of a study that showed that vaccine-generated mpox antibodies largely waned 6 to 12 months after administration of Jynneos, developed in 2019 by Bavarian Nordic (BVNRY), CIDRAP reported yesterday. Bavarian Nordic and Emergent BioSolutions (EBS) are the makers of the only two vaccines that the U.S. CDC currently recommends for mpox. In late 2023, GeoVax Labs (GOVX) announced that it had amended a previously executed Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases to expand GeoVax’s commercial license to include mpox and smallpox as additional indications.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue